StockNews.com initiated coverage on shares of Calithera Biosciences (NASDAQ:CALA – Free Report) in a report released on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.
Calithera Biosciences Stock Performance
CALA stock opened at $0.03 on Friday. Calithera Biosciences has a twelve month low of $0.01 and a twelve month high of $0.50. The business has a 50 day moving average price of $0.03 and a two-hundred day moving average price of $0.04.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of CALA. Goldman Sachs Group Inc. lifted its holdings in Calithera Biosciences by 143.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 72,865 shares during the last quarter. Renaissance Technologies LLC lifted its position in Calithera Biosciences by 13.8% during the third quarter. Renaissance Technologies LLC now owns 114,555 shares of the biotechnology company’s stock worth $337,000 after acquiring an additional 13,855 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Calithera Biosciences in the first quarter valued at approximately $404,000. Affinity Asset Advisors LLC acquired a new stake in Calithera Biosciences during the 1st quarter worth approximately $404,000. Finally, Vanguard Group Inc. grew its holdings in Calithera Biosciences by 23.4% in the 3rd quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company’s stock valued at $415,000 after buying an additional 26,800 shares in the last quarter. 0.02% of the stock is currently owned by institutional investors and hedge funds.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc was incorporated in 2010 and is headquartered in South San Francisco, California.
- Five stocks we like better than Calithera Biosciences
- Dividend Capture Strategy: What You Need to Know
- 3 attractive stocks that insiders are buying
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Golden Cross Stocks: Pattern, Examples and Charts
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.